(S)-1,2-Bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic Acid

(S)-1,2-Bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic Acid

(S)-1,2-Bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid (Chinese name: (S)-1,2-双(叔丁氧羰基)六氢哒嗪-3-羧酸; CAS 156699-39-7) is the N,N'-di-Boc-protected form of (3S)-piperazic acid, i.e. of the hydrazine-containing cyclic non-proteinogenic amino acid (3S)-hexahydropyridazine-3-carboxylic acid.
Send Inquiry

English synonyms : (S)-1,2-Bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid

English synonyms:(S)-1,2-Bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid;(S)-1,2-Bis(Boc)-hexahydropyridazine-3-carboxylic acid;(S)-Tetrahydropyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester;(3S)-1,2-Bis(tert-butoxycarbonyl)-1,2-diazinane-3-carboxylic acid;(3S)-1,2-Bis[(2-methylpropan-2-yl)oxycarbonyl]diazinane-3-carboxylic acid;1,2,3-Pyridazinetricarboxylic acid, tetrahydro-, 1,2-bis(1,1-dimethylethyl) ester, (3S)-;SCHEMBL13303532

CAS number :156699-39-7

Molecular formula : C15H26N2O6

Molecular weight :330.38

Properties: White to off-white solid

Content: 95%~98%(HPLC) Professional scientific accurate detection

Function: Used in foreign trade export, scientific research and chemical reagents and other fields; it is employed mainly as a chiral building block (N,N'-di-Boc-protected piperazic acid) for introducing piperazic acid residues into peptides, macrocycles and other drug candidates.

Packing: 1G 100G 500G 1KG

Storage: Dry, sealed and protected from light, store at 2-8℃, shelf life of 2 years

 

Structural formula:

product-520-380

 

(S)-1,2-Bis(Boc)-hexahydropyridazine-3-carboxylic acid use and synthesis method

 

Intro

(S)-1,2-Bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid (Chinese name: (S)-1,2-双(叔丁氧羰基)六氢哒嗪-3-羧酸; CAS 156699-39-7) is the N,N'-di-Boc-protected form of (3S)-piperazic acid, i.e. of the hydrazine-containing cyclic non-proteinogenic amino acid (3S)-hexahydropyridazine-3-carboxylic acid. Both ring nitrogens are masked as tert-butoxycarbonyl (Boc) carbamates while the C3 carboxylic acid remains free, so the compound can be used directly in standard amide-bond-forming chemistries to install a conformationally constrained piperazic acid unit into peptides, depsipeptides and macrocyclic drug candidates. It is classified by suppliers as a pharmaceutical intermediate of the pyridazine (hexahydropyridazine) family and is offered at 95-98% purity (HPLC).

 

Peculiarity

The molecule combines three features that make it a practical synthetic building block: (i) a six-membered, saturated N-N (hydrazine) ring that behaves as a rigid proline/dipeptide isostere and adopts defined turn-like geometries; (ii) two acid-labile Boc groups that suppress the nucleophilicity and oxidation sensitivity of the ring hydrazine and impart good solubility in common organic solvents (DCM, THF, DMF, EtOAc), and that can be removed selectively with HCl/dioxane or TFA to liberate the free hydrazine late in a synthesis; (iii) a single defined stereocentre at C3 in the (S)-configuration, together with a free carboxylic acid for chain extension. Key data: molecular formula C15H26N2O6, molecular weight 330.38 (monoisotopic mass 330.179), MDL MFCD23099733, PubChem CID 10871237, InChIKey MLXHSDCSBUGOLZ-JTQLQIEISA-N; calculated (ACD/Labs) values: boiling point 422.0 ± 55.0 °C at 760 mmHg, density 1.200 ± 0.06 g/cm3, pKa 3.74 ± 0.20, flash point ca. 209 °C, refractive index ca. 1.503 - these are predicted, not measured, figures. Safety classification: GHS07, Warning, H302 + H312 + H332.

 

Uses

This compound is a synthetic intermediate, not a drug substance, and has no pharmacological activity of its own; its importance comes from the piperazic acid residue it installs. Piperazic acid was first identified in the monamycin antibiotics and is found today in several classes of bioactive compounds; protected piperazic acid intermediates are described as key intermediates for angiotensin-converting enzyme (ACE) inhibitors, caspase / interleukin-1β converting enzyme (ICE) inhibitors and type IV collagenase (matlystatin-type) inhibitors. The most prominent current example is the piperazic acid residue retained in daraxonrasib (RMC-6236; CAS 2765081-21-6; C44H58N8O5S, MW 811.06), an oral RAS(ON) multi-selective tri-complex inhibitor discovered by Revolution Medicines - its IUPAC name contains a [1,2]diazinane ring and reported structures show the N-N-C(=O) piperazic motif. Daraxonrasib was approved by the U.S. FDA on 26 August 2026 (brand name RASONQUE) for adults with previously treated metastatic pancreatic adenocarcinoma.

Synthesis and representative transformations

Production routes reported for (3S)-piperazic acid derivatives start either from the chiral pool or from hydrazine chemistry. In the chiral-pool approach (Robidoux et al., US 2003/0176691 A1 = WO 2001/083458 A2) (3S)-piperazic acid is obtained from D-glutamic acid through an (R)-2,5-dihydroxyvalerate ester that is converted into a bis-leaving group and cyclised with a bis-protected hydrazine; the (3R)-enantiomer is obtained analogously from L-glutamic acid. A process route (EP 1104409 B1) treats a 1,4-dihaloalkyl ester with an N,N'-bis-protected hydrazine in DMF in the presence of a water scavenger, metal hydroxide and phase-transfer catalyst, giving the protected piperazic acid in improved yield. An enzymatic/biological route (Washington University, US 2019/0002936 A1) produces L-piperazic acid from L-ornithine via N5-hydroxy-ornithine cyclase/dehydratase. The commercial product is then typically obtained by double Boc protection (Boc2O, aqueous alkali) followed by acidification and isolation. Typical downstream chemistry includes esterification, amide coupling at the free C3-carboxylic acid and acidolytic removal of one or both Boc groups.

Starting materials: (3S)-Piperazic acid (hexahydropyridazine-3-carboxylic acid) or its ester; di-tert-butyl dicarbonate (Boc2O); bases such as NaOH or Na2CO3 in dioxane/water or THF/water.

Reagents and conditions (protection step): Boc2O 2.0-2.5 equiv, aqueous alkaline medium, 0 °C to room temperature; after completion acidify to pH 2-3 and isolate the di-Boc product by extraction, trituration or crystallisation.

Representative transformations: esterification of the C3-carboxylic acid; amide coupling with amines using T3P/DIPEA or HATU/DIPEA in DMF; selective or complete deprotection with HCl in dioxane or TFA in dichloromethane to release the ring hydrazine for acylation or macrocyclisation.

Yields and specifications: the protection step and subsequent couplings proceed in good to high yield under the above conditions; commercial material is normally specified at 95-98% purity (HPLC), white to off-white solid, single (3S)-enantiomer.

Hot Tags: (s)-1,2-bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid, China (s)-1,2-bis(tert-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid suppliers, 1118767-16-0, 1169630-82-3, bulk drugs and intermediates, Intermediate Oseltamivir Phosphate Prevents Influenza, Rocuronium Bromide Intermediate Neuromuscular Blocking Agent, Semaglutide intermediates